

PIRAMAL ENTERPRISES LIMITED
Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400 070
STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE MONTHS AND YEAR ENDED MARCH 31, 2019

Particulars	Three months ended 31/03/2019	Three months ended 31/12/2018	Corresponding Three months ended 31/03/2018	Year to date figures for current year ended 31/03/2019	(Rs.in Crores) Previous Year ended 31/03/2018
	(Audited) (Refer Note 1)	(Unaudited)	(Audited) (Refer Note 1)	(Audited)	(Audited)
Revenue from operations	1,012.61	890.35	1,003.01	3,671.40	3,296.95
Other income (Net) (Refer Note 5)	29.61	(63.72)	261.90	446.32	639.79
Total Income	1,042.22	826.63	1,264.91	4,117.72	3,936.74
Expenses					
Cost of materials consumed	193.50	193.33	202.10	767.27	809.73
Purchases of stock-in-trade	28.08	28.14	24.04	97.36	100.73
Changes in inventories of finished goods, stock-in-trade and work-in-progress	92.57	(41.39)	68.64	9.74	(24.84)
Excise duty	-	-	-	-	8.32
Employee benefits expense	85.33	110.12	126.83	405.45	442.72
Finance costs	450.76	417.30	275.59	1,496.61	989.55
Depreciation and amortisation expense	33.37	33.13	31.13	131.18	111.58
Other expenses (Net)	239.78	184.26	165.25	713.73	745.50
Total Expenses	1,123.39	924.89	893.58	3,621.34	3,183.29
Profit/(Loss) Before Exceptional Item and Tax	(81.17)	(98.26)	371.33	496.38	753.45
Exceptional item (Refer Note 4)	-	-	-	(1,287.96)	-
Profit/(Loss) Before Tax	(81.17)	(98.26)	371.33	(791.58)	753.45
Tax Expense					
(1) Current tax (including tax expense of prior years)	(19.37)	(4.83)	83.51	71.57	175.38
(2) Deferred tax	0.40	(25.96)	42.71	(1.17)	59.60
Profit/(Loss) After Tax	(62.20)	(67.47)	245.11	(861.98)	518.47
Other Comprehensive Income and (Expense) (OCI)					
A. Items that will not be subsequently reclassified to profit or loss					
(a) Changes in fair values of equity instruments through OCI	255.95	159.35	(78.24)	(551.69)	667.11
(b) Remeasurement of Post Employment Benefit Obligations	(0.18)	(0.66)	(1.68)	(3.02)	(5.52)
Income tax impact on above	0.05	0.23	(22.37)	24.00	(21.04)
B. Items that will be subsequently reclassified to profit or loss					
Deferred gains/(losses) on cash flow hedge	5.27	11.51	(1.15)	5.61	(0.20)
Income tax impact on above	(1.84)	(3.97)	0.40	(1.96)	0.07
Total Other Comprehensive Income / (Expense), Net of Tax Expense	259.25	166.46	(103.04)	(527.06)	640.42
Total Comprehensive Income / (Loss), Net of Tax Expense	197.05	98.99	142.07	(1,389.04)	1,158.89
Paid-up Equity Share Capital (Face Value of Rs.2/- each)	36.89	36.68	36.05	36.89	36.05
Reserves (excluding Revaluation Reserves)				19,484.17	21,300.80
Net Worth (Refer Footnote 1)				17,162.67	18,978.46
Paid up Debt Capital				7,863.89	4,434.00
Debenture Redemption Reserve				1,516.88	690.23
Earnings Per Equity Share (EPS) (Face Value of Rs.2/- each) (not annualised) (Refer Note 8(a))					
a) Basic EPS for the period/year (Rs.)	(3.13)	(3.40)	12.66	(43.40)	28.52
b) Diluted EPS for the period/year (Rs.)	(3.13)	(3.40)	12.64	(43.40)	28.51
Debt Equity Ratio (Refer Footnote 2)				0.9	0.7
Debt Service Coverage Ratio (Refer Footnote 3)				0.7	0.6
Interest Service Coverage Ratio (Refer Footnote 4)				1.3	1.8

See accompanying notes to the financial results


Piramal Enterprises Limited
 (Formerly Known as Piramal Healthcare Limited)
 CIN : L24110MH1947PLC005719

Registered Office: Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai 400 070 India

T +91 22 3802 3000 / 4000

piramal.com

Additional Information:

The following additional information is presented to disclose the effect on net profit after tax, Basic and Diluted EPS, without the effect of exceptional item (Refer Note 4).

Particulars	(Rs. in Crores)
	Year to date figures for current year ended 31/03/2019
Loss After Tax As reported in the standalone financial results	(861.98)
Add: Impact of Exceptional item	1,287.96
Adjusted Profit After Tax	425.98
Basic EPS for the period (Rs.) (Refer Note 8(a))	
As reported in the standalone financial results	(43.40)
Add: Impact of Exceptional item	64.85
Adjusted Basic EPS	21.45
Diluted EPS for the period (Rs.) (Refer Note 8(a))	
As reported in the standalone financial results	(43.40)
Add: Impact of Exceptional item	64.76
Adjusted Diluted EPS	21.36

Footnotes:

1. Net Worth = Share Capital + Other Equity (excluding Capital Reserve)
2. Debt equity Ratio:
Debt = Long term Borrowings + Short term Borrowings + Current maturities of Long term Borrowings
Equity = Paid up Share Capital+ Other Equity
3. Debt Service Coverage Ratio = (Earnings before Interest, Tax and Exceptional items) / (Interest Expense + Principal Repayment of Debt excluding loans transferred)
Debt = Long Term Debt
Interest Expense = Interest on Long Term Debt
4. Interest Service Coverage Ratio = (Earnings before Interest, Tax and Exceptional items) / Interest Expense



Notes:

1. The audited standalone financial statements for the year ended March 31, 2019 have been taken on record by the Board of Directors at its meeting held on April 26, 2019. The statutory auditors have expressed an unqualified audit opinion on the financial results for the year ended March 31, 2019. These Standalone financial results have been extracted from the audited standalone financial statements. Figures for the three months ended March 31, 2019 and 2018 represent the difference between the audited figures in respect of full financial years and the published figures for the nine months ended December 31, 2018 and 2017, respectively.

2. Statement of Standalone Assets and Liabilities :

Particulars	(Rs.in Crores)	
	As at	
	31/03/2019 (Audited)	31/03/2018 (Audited)
ASSETS		
1. Non-Current Assets		
(a) Property, Plant & Equipment	1,435.43	1,381.79
(b) Capital Work in Progress	45.91	77.18
(c) Intangible Assets	388.20	425.40
(d) Intangible Assets under development	52.04	34.53
(e) Financial Assets:		
(i) Investments	22,049.36	20,867.45
(ii) Loans	10,333.38	8,393.58
(iii) Other Financial Assets	31.41	53.03
(f) Deferred Tax Assets (Net)	292.59	269.38
(g) Other Non-Current Assets	467.44	295.47
Total Non-Current Assets	35,095.76	31,797.81
2. Current Assets		
(a) Inventories	366.67	382.58
(b) Financial Assets:		
(i) Investments	969.32	2,863.13
(ii) Trade Receivables	619.06	492.96
(iii) Cash & Cash equivalents	23.39	521.94
(iv) Bank balances other than (iii) above	41.69	32.88
(v) Loans	265.60	248.97
(vi) Other Financial Assets	328.58	133.38
(c) Other Current Assets	295.60	258.49
Total Current Assets	2,909.91	4,934.33
Total Assets	38,005.67	36,732.14
EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share capital	36.89	36.05
(b) Other Equity	19,484.17	21,300.80
Total Equity	19,521.06	21,336.85
Share Application money pending Allotment	4.18	-
2. Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities:		
(i) Borrowings	4,619.83	4,011.56
(ii) Other Financial Liabilities	0.74	3.54
(b) Provisions	36.66	28.02
(c) Other Non-Current Liabilities	125.16	-
Total Non-Current Liabilities	4,782.39	4,043.12
Current Liabilities		
(a) Financial Liabilities:		
(i) Borrowings	6,616.19	7,979.17
(ii) Trade Payables		
(a) Total outstanding dues of Micro enterprises and small enterprises	6.61	4.47
(b) Total outstanding dues of creditors other than Micro enterprises and small enterprises	558.19	539.10
(iii) Other Financial Liabilities	6,335.87	2,725.47
	13,516.86	11,248.21
(b) Other Current Liabilities	66.91	51.21
(c) Provisions	43.51	45.46
(d) Current Tax Liabilities (Net)	70.76	7.29
Total Current Liabilities	13,698.04	11,352.17
Total Equity & Liabilities	38,005.67	36,732.14



3. Segment Wise Revenue, Results and Capital Employed
(Rs. in Crores)

Particulars	Three months ended 31/03/2019	Three months ended 31/12/2018	Corresponding Three months ended 31/03/2018	Year to date figures for Current Year ended 31/03/2019	Previous Year ended 31/03/2018
	(Audited) (Refer Note 1)	(Unaudited)	(Audited) (Refer Note 1)	(Audited)	(Audited)
1. Segment Revenue					
Total Income from Operations, Net					
a. Pharmaceuticals	687.03	498.55	649.99	2,181.65	2,037.90
b. Financial Services	325.58	391.80	353.02	1,489.75	1,259.05
Total Income from Operations, Net	1,012.61	890.35	1,003.01	3,671.40	3,296.95
2. Segment Results					
a(i) Pharmaceuticals (before exceptional item) #	149.87	49.47	243.82	571.21	582.28
a(ii) Less : Exceptional Item (Refer Note 4)	-	-	-	1,287.96	-
a(iii) Pharmaceuticals (after exceptional item)	149.87	49.47	243.82	(716.75)	582.28
b. Financial Services	(79.74)	53.85	166.40	266.63	458.84
Total (a(iii))+b	70.13	103.32	410.22	(450.12)	1,041.12
Less: Depreciation and Amortisation expense	33.37	33.13	31.13	131.18	111.58
Less: Finance Costs (unallocated)	120.81	100.85	84.21	391.72	356.35
Add : Net unallocated income / (Net unallocated expense)	2.88	(67.60)	76.45	181.44	180.26
Total Profit/(loss) Before Tax	(81.17)	(98.26)	371.33	(791.58)	753.45
#Segment Results of Pharmaceuticals Segment includes foreign exchange gain/(loss) :	(4.40)	(5.86)	128.18	73.32	231.52
3. Capital Employed					
(Segment Assets - Segment Liabilities)					
a. Pharmaceuticals					
Segment Assets	3,512.45	3,468.29	5,730.51	3,512.45	5,730.51
Segment Liabilities	(729.89)	(737.89)	(754.93)	(729.89)	(754.93)
b. Financial Services					
Segment Assets	27,734.90	28,611.74	25,285.11	27,734.90	25,285.11
Segment Liabilities	(12,790.39)	(13,757.48)	(10,394.40)	(12,790.39)	(10,394.40)
c. Unallocated					
Segment Assets	6,758.32	6,589.72	5,716.52	6,758.32	5,716.52
Segment Liabilities	(4,960.15)	(4,875.53)	(4,245.96)	(4,960.15)	(4,245.96)
Total Capital Employed	19,525.24	19,298.85	21,336.85	19,525.24	21,336.85

Note:

Segment results of Pharmaceuticals segment represent Earnings before Interest, Tax, Depreciation and Amortisation (adjusted for exceptional item) and Segment results of Financial Services represent Earnings before Tax, Depreciation and Amortisation.



4. In June 2018, the Company's wholly owned subsidiary, Piramal Holdings (Suisse) SA (referred to as "PHSA") sold its entire ownership interest in its wholly owned subsidiary Piramal Imaging SA. Consequently, the Company's cost of equity investment in PHSA amounting to Rs. 1,287.96 Crores have been provided for.

5. Other income (Net) includes the net effect of Foreign Exchange Gain/(Loss) :

(Rs. in Crores)

Particulars	Three months ended 31/03/2019	Three months ended 31/12/2018	Corresponding Three months ended 31/03/2018	Year to date figures for Current Year ended 31/03/2019	Previous Year ended 31/03/2018
Exchange Gain/(Loss), Net	(36.91)	(120.10)	140.86	80.02	251.57

6. Effective April 1, 2018, the Company adopted Ind AS 115 - Revenue from contracts with customers, using the cumulative catch-up transition method which is applied to contracts that were not completed as of April 1, 2018. Accordingly, the comparatives have not been retrospectively adjusted. The effect of adoption of Ind AS 115 is insignificant.

7. On October 25, 2017, 464,330 Compulsorily Convertible Debentures ("CCD") having face value of Rs. 107,600 per CCD were allotted to the CCD holders for an aggregate amount of Rs. 4,996.19 Crores. Each CCD is convertible into 40 equity shares of Rs. 2 each. Out of this, 225,000 equity shares were allotted by the Company pursuant to optional conversion of 5,625 CCDs by the CCD holders in the previous year.

During the year ended March 31, 2019, 4,162,000 equity shares were allotted by the Company pursuant to optional conversion of 104,050 CCDs by the CCD holders.

Subsequent to March 31, 2019:

- 548,120 Equity shares were allotted by the Company pursuant to optional conversion of 13,703 CCDs; and
- 13,638,080 Equity shares were allotted pursuant to compulsory conversion of outstanding 340,952 CCDs on maturity.

8. (a) On March 8, 2018, the Company had issued 8,310,275 Equity shares under Rights Issue at a price of Rs. 2,380 per share (including premium of Rs.2,378 per share). Out of the aforesaid issue, 11,298 and 7,485,574 equity shares were allotted by the Company during the year ended March 31, 2019 and year ended March 31, 2018, respectively.

Subsequent to March 31, 2019, 17,585 Equity shares were allotted by the Company under Rights Issue at a price of Rs. 2,380 per share (including premium of Rs.2,378 per share) to the CCD holders out of the Right Equity shares reserved for them (as per regulation 53 of erstwhile Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009).

Earnings per share (Basic and Diluted) for three months and year ended March 31, 2018 has been retrospectively adjusted for effect of Rights Issue stated above.

As on March 31, 2019, 788,764 Rights Equity shares have been reserved for the CCD Holders (as per regulation 53 of erstwhile Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009) and 24,639 Rights Equity Shares have been kept in abeyance. Of the said 788,764 reserved equity shares, CCD holders did not exercise the right to subscribe for 154,377 Rights Equity shares. These unsubscribed rights and also those arising in future, if any, shall be dealt with, in accordance with the law, post conversion of all the outstanding CCDs into equity shares and hence are considered to be dilutive in nature. Consequent to the loss for the three months ended December 31, 2018 and three months and year ended March 31, 2019, after exceptional item, potential equity shares are considered as anti-dilutive and hence diluted EPS is the same as basic EPS.

(b) Proceeds from the rights issue have been utilised upto March 31, 2019 in the following manner :

(Rs. in Crores)

Particulars	Planned	Actual till 31/03/2018	Actual till 31/03/2019
a) Investment in Piramal Capital and Housing Finance Limited (formerly known as Piramal Housing Finance Limited) (wholly owned subsidiary)	750.00	750.00	750.00
b) Repayment or pre-payment, in full or part, of certain borrowings availed by the Company	1,000.00	878.91	1,000.00
c) General Corporate Purposes	216.22	-	27.98
Add: Issue related expenses	11.63	6.05	8.65
Total	1,977.85	1,634.96	1,786.63
Less : Rights Shares held in Abeyance	(5.86)	-	-
Less : Rights Shares reserved in favour of Compulsorily Convertible Debenture Holders (Refer note 8(a))	(187.73)	-	-
Less : Interest Income received from Fixed Deposits placed with Banks from Rights Issue Proceeds	-	(1.39)	(2.92)
Total	1,784.26	1,633.57	1,783.71
Unutilised proceeds kept as Fixed Deposit with Bank	-	148.00	-
Unutilised proceeds kept in Escrow Account	-	-	0.55

9. The secured listed non-convertible debentures of the Company aggregating Rs.7,738.89 Crores as on March 31, 2019 are secured against specified receivables (including those relating to a wholly owned subsidiary) and a first ranking pari passu mortgage over Specifically Mortgaged Property.

The Asset cover on the secured listed non-convertible debentures of the Company exceeds hundred percent of the principal amount of the said debentures.

10. During the year ended March 31, 2019, the Company transferred certain financial assets of Rs. 2,207.72 crores (Previous Year : Rs. 3,001.67 crores) and certain financial liabilities of Rs. NIL (Previous Year : Rs. 1,272.19 crores) to Piramal Capital and Housing Finance Limited and financial assets of Rs. 694.41 crores (Previous Year : Rs. NIL) to PHL Fininvest Private Limited, both wholly owned subsidiaries, for an aggregate consideration of Rs. 2,902.13 crores (Previous Year: Rs. 1,729.48 crores). Accordingly the results for the year ended March 31, 2019 are not comparable with the results of the previous year.

11. The Board of Directors on May 28, 2018 had approved a "Scheme of Amalgamation" ("Scheme") of Piramal Phytocare Limited, an associate of the Company, with the Company and its respective shareholders. The Scheme has been approved by the equity shareholders of the Company in their meeting convened as per the directions of the National Company Law Tribunal on April 2, 2019. The Scheme is subject to approval of regulatory authorities.



12. A Dividend of Rs. 28 per equity share (face value of Rs. 2/- each) has been recommended by the Board of Directors which is subject to approval of Shareholders.

For **PIRAMAL ENTERPRISES LIMITED**

Atay G. Piramal
Chairman



April 26, 2019, Mumbai